In light of those results, two patients with relapsing/refractory B-cell lymphoma received pretreatment with decitabine before infusion of CD19-specific CAR-T cells, leading to complete remission in both patients [21]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.